8 key facts about Indias biologic manufacturing landscape

www.terrapinn.com/bio-india

d d Driving the industry by building the pillars of Indias biologic manufacturing industry, Reliance Life Sciences established and funded the Reliance Institute of d Life Sciences an autonomous institution for higher education. d Presenting at Biologic Manufacturing World Asia, is the Director of Reliance d Institute of Life Sciences Arnab Kapat who also takes on the role of Vice d President and Head of Peptide Therapeutics initiative in Reliance Life Sciences Hdhhhjghjghjghjghj Fd

d d India is no longer polio endemic but the burden of meningococcal disease d Today, between outbreaks in India is difficult to quantify. Hib, acellular Pertussis & d Inactivated Polio vaccination concepts was introduced in India through the of Pasteur Merieux Connaught, now Sanofi pasteur in South Asia. It d creation also set a benchmark in premium pricing with acellular Pertussis vaccine. R.K. d Suri, today the Chief Executive, Biologicals of Panacea Biotec, was a key driver for launching these concepts in India. Hdhhhjghjghjghjghj d f

www.terrapinn.com/bio-india

d d Globally, the pharmaceutical landscape is going through a period of change. Indias pharmaceutical industry ranks third in terms of pharmaceutical d production (by volume) and 14th in terms of value . As growth in developed d markets slows down the emerging markets (including India) will become more and more valuable to the industry as a whole. d d Hdhhhjghjghjghjghj Fd

d d Karkaria is currently President of the Biotechnology division of Lupin d Cyrus Pharma is based in Pune. Prior to that he was Vice President at Celldex d Therapeutics and CuraGen Corporation in New Haven, Connecticut, USA heading rations and Biopharmaceutical Process Sciences. He has also held positions d Ope at Biogen Idec and Scios. He has been part of teams that have developed multi d billion $ blockbusters in the field of neurology, immunology and oncology such as Avonex, Amevive and Tysabri (Biogen Idec) from the bench to manufacturing Hdhhhjghjghjghjghj scale (2000L to 15,000L). As part of the commercialization process he has also d faced Regulatory bodies from the US FDA, EMEA, Australian TGA etc., through f pre-IND to BLA filings.

www.terrapinn.com/bio-india

d d Dr. M.K. Sahib is currently Director, Genomics and Biotechnology at Wockhardt where he started and established the Biotechnology Research Center at d Wockhardt. He led the R&D Team for successful development of biosimilars, d vaccines and fermentation products that contributed to meeting Indias medical needs including Insulin (WOSULIN) and its analogs, Erythropoietin (WEPOX), d Hepatitis B (BIOVAC B) vaccine and more. d Hdhhhjghjghjghjghj d f

d d Institute of India is the World's 5th largest vaccine manufacturer (by d Serum volume) where every 1 out of every 2 children immunized worldwide gets at d least one vaccine produced by Serum Institute. d d Hdhhhjghjghjghjghj Fd

www.terrapinn.com/bio-india

d Bharat Biotech has delivered over 2 billion doses of vaccines in over 65 countries. d Founder , Chairman and Managing Director, Krishna Ella is also involved in shaping Indias science education and policy as well as International collaboration d by being a Member, Advisor or Chairman of numerous committees. The d prominent ones among these include Five Year Plan for Biotechnology, Human Resource and Innovation, National Biotech Policy, High Technology Cooperation d Groups, National Task Force in Industrial Biotechnology, National Council of IPR. d He has recently been nominated as a Member of the Scientific Advisory Committee to the Prime Minister of India. Hdhhhjghjghjghjghj Fd

d d first indigenous Influenza Vaccine (H1N1) was introduced by Reinhard d India's Glueck, Chief Scientific Officer of Zydus Cadila where he is responsible for the d Vaccine Technology Center (VTC) and the construction of a state of the art global d vaccine unit. D At the point of introduction, H1N1 had already claimed the lives of over 1,000 in The current programs under development at Zydus Cadila include vaccine d India. candidates designed to address infectious diseases like next-generation Influenza, f Measles-Mumps-Rubella-Varicella, Typhoid, DPT-HiB, Hepatitis-B, Hepatitis-A,
Hepatitis-E, Japanese Encephalitis, HPV and combination vaccines.

www.terrapinn.com/bio-india

Wed love to hear your views on all of this

Join the conversation
Click here to visit our Total BioPharma blog

Click here to contribute to our LinkedIn discussion

Click here to follow us on Twitter @totalbiopharma

Subscribe to enewsletter

Click here to sign up for Total BioPharma e-newsletter

www.terrapinn.com/bio-india

Wed love to meet you too

Were hosting the BioPharma India Convention, in Mumbai, India , from the 25th- 26th of November and wed love to see you there. BioPharma India is the regions leading biopharma event. Biologic Manufacturing World, (part of the BioPharma India Convention) brings together senior decision makers from biologic manufacturers and CMOs to learn and discuss strategies in advancing manufacturing capabilities and outsourcing opportunities in India.

If you would like to be part of this interactive conference, contact:

Rebecca Koh General Manager Rebecca.koh@terrapinn.com +65 6322 2725

Source: http://www.boehringer-ingelheim.com/global_activities/aaa/india/facts_and_figures.html Disclaimer This publication contains general information only, and none of Terrapinn Limited, its members, or their related entities (collectively, Terrapinn) is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Terrapinn shall be responsible for any loss whatsoever sustained by any person who relies on this publications.